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ABSTRACT
Objective To independently evaluate the performance of
the QRISK score for predicting 10 year risk of
cardiovascular disease in an independent UK cohort of
patients from general practice and compare the
performance with Framingham equations.
Design Prospective open cohort study.
Setting 274 practices from England and Wales
contributing to the THIN database.
Participants 1.07 million patients, registered between 1
January 1995 and 1 April 2006, aged 35-74 years (5.4
million person years) with 43990 cardiovascular events.
MainoutcomemeasuresFirstdiagnosisofcardiovascular
disease (myocardial infarction, coronary heart disease,
stroke, and transient ischaemic attack) recorded in
general practice records.
ResultsThis independentvalidationindicatedthat QRISK
offers an improved performance in predicting the 10 year
risk of cardiovascular disease in a large cohort of UK
patients over the Anderson Framingham equation.
Discrimination and calibration statistics were better with
QRISK. QRISK explained 32% of the variation in men and
37% in women, compared with 27% and 31%
respectively for Anderson Framingham. QRISK
underpredicted risk by 13% for men and 10% for women,
whereas Anderson Framingham overpredicted risk by
32%formenand10%forwomen.Intotal,85010(8%)of
patients would be reclassified from high risk (≥20%) with
Anderson Framingham to low risk with QRISK, with an
observed 10 year cardiovascular disease risk of 17.5%
(95% confidence interval 16.9% to 18.1%) for men and
16.8%(15.7%to18.0%)forwomen.Theincidencerateof
cardiovascular disease events among men was 30.5 per
1000personyears(95%confidenceinterval29.9to31.2)
in high risk patients identified with QRISK and 23.7 per
1000 person years (23.2 to 24.1) in high risk patients
identified with Anderson Framingham. Similarly, the
incidence rate of cardiovascular disease events among
women was 26.7 per 1000 person years (25.8 to 27.7) in
high risk patients identified with QRISK compared with
22.2 per 1000 person years (21.4 to 23.0) in high risk
patients identified with Anderson Framingham.
Conclusions The QRISK cardiovascular disease risk
equationoffersanimprovementoverthelongestablished
Anderson Framingham equation in terms of identifying a
high risk population for cardiovascular disease in the
United Kingdom. QRISK underestimates 10 year
cardiovascular disease risk, but the magnitude of
underprediction is smaller than the overprediction with
Anderson Framingham.
INTRODUCTION
Risk prediction models can play an important role in
decision making and future management of individual
or groups of patients with a particular medical
condition.
1 Such models are designed, in principle, to
estimate or predict the probability or risk of a patient
developingsomefutureclinicaleventbasedonanum-
ber of patient and disease characteristics.
Unfortunately, of the overwhelming plethora of risk
score indices published every year most make no clin-
icalimpact,offerlittleinthedesignoffutureprognostic
studies and subsequently disappear into the archives.
2
Todate,theabsenceofexplicitvalidationguidelinesor
indeed reporting guidelines for risk prediction has
hampered the quality and clarity of published studies.
Studiesoftenhavesimilarmethodologicalproblemsto
other types of studies: poor design, small sample size,
incompletedata,inappropriatestatisticalanalyses,and
optimistic interpretation are concerns. In addition,
there is a general lack of convincing external
validation.
3
The latter point, external validation, is an essential
step in any risk model development in order to evalu-
ate and show transportability of the model so that it
could be applied with confidence on a cohort other
than the derivation cohort.
45 Box and Draper aptly
put it: “All models are wrong; the practical question
is how wrong do they have to be to not be useful.”
6
The act of validation is thus merely quantifying and
judging how useful (or not) the model is in estimating
the risk of developing a particular outcome.
The interpretation of the results from studies devel-
opingandvalidatingriskpredictionmodelsistoooften
focusedonclassifyingpatientsintoriskgroups,relying
mainlyonreceiveroperatingcharacteristiccurves,and
neglectstheaccuracyoftheactualriskprediction(cali-
bration).Accuratepredictioniscrucialasanysystema-
tic overprediction would inevitably lead to a
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treatment, affecting healthcare resources and poten-
tially exposing patients to unnecessary treatments.
Similarly, any systematic underprediction of risk
could potentially deny patients much needed treat-
ment.
QRISK, a new multifactor cardiovascular disease
risk prediction algorithm, was recently developed
and validated for use in the United Kingdom. Initial
results describing the derivation and internal valida-
tionwerepublishedinJuly2007.
7QRISKincludestra-
ditionalcardiovasculardiseaseriskfactors—(1)age,(2)
sex,(3)systolicbloodpressure,(4)smokingstatus,and
(5) serum cholesterol: high density lipoprotein ratio—
that are incorporated in the long established Framing-
ham risk equations,
8 but it also includes (6) body mass
index, (7) family history of cardiovascular disease, (8)
socialdeprivation(Townsendscore),
9and(9)theuseof
antihypertensivetreatment.WenoteQRISKexcludes
patients with a pre-existing diagnosis of diabetes and
does not include electrocardiogram assessment of left
ventricular hypertrophy, both included in Framing-
ham. The development of QRISK made use of elabo-
rate statistical methods such as fractional poly-
nomials
10 to model any non-linear risk relationships
with continuous variables and multiple imputation
methods
11 to avoid potentially biased estimates
obtained from a reduced complete-case dataset.
In response to a number of critiques of the original
BMJpapers,
12theQRISKauthorsundertookarevision
toaccountforstatinuseandimplementedanimproved
approach to multiple imputation method to account
for missing data. They then applied this revised
model on an external dataset (THIN) in a second vali-
dation study to assess model performance.
13
Despite the two published papers on the develop-
ment and validation of QRISK, on impressively large
cohorts, showing a more than competitive perfor-
mance when compared with the Anderson Framing-
ham and ASSIGN equations,
14 the National Institute
for Health and Clinical Excellence (NICE) has not
recommended QRISK and has recommended contin-
ued use of Framingham.
15 In addition, despite Fra-
mingham’s limitations and known shortcomings,
16-19
NICE has recommended an unexplained adjustment
factor to adjust for family history and ethnicity
20 (eth-
nicityisnotariskfactorintheversionofQRISKinthis
paper).However,thisadjustedAndersonFramingham
approachhas,todate,notundergoneanyvalidationor
peer reviewed consultation in the public domain. The
QRISK developers have also been criticised for not
making the QRISK algorithm publicly available so
that head-to-head comparison can be made.
21 Finally,
an unpublished report, attempting to revalidate the
QRISK model on the THIN cohort, failed to replicate
the results of the external validation and has further
contributed doubts about the performance of
QRISK.
22 This report has subsequently been shown
to be incorrect and misleading and based on an incor-
rect and naive specification of a model, and to date it
has not been made available in the public domain.
23
This article describes and synthesises the results
from an independent and external evaluation of
QRISK commissioned by the Department of Health
and compares the performance of QRISK against the
Anderson Framingham equation
8 currently recom-
mended by NICE.
20 In addition, we compare QRISK
with a recently developed sex-specific Framingham
risk equation.
24 This article presents additional mate-
rial on the performance of QRISK currently not pre-
sentedelsewhere.AstheQRISKequationhasnotbeen
made available in the public domain, we emphasise
thatweweregrantedfullaccessbytheQRISKauthors
totheQRISKalgorithmandaccompanyingdocumen-
tation, enabling an accurate implementation. In addi-
tion, we were granted permission to use the THIN
dataset by EPIC Database Research Company.
METHODS
Study population
Forthisindependentvalidationandverificationanaly-
sis of QRISK, we used patients from the THIN data-
base (www.thin-uk.com) as described by Hippisley-
Cox et al
13 who were registered between 1 January
1995 and 31 March 2006. Patients were excluded if
they had a prior diagnosis of cardiovascular disease,
had invalid dates or invalid recorded risk factor values
out of plausible range, were under the age of 35 years,
were aged 75 years or over, were missing Townsend
scores,hadadiagnosisofpre-existingdiabetes,orwere
prescribed statins at baseline.
Table 1 |Characteristics of 1 072 800 patients from the THIN database. Values are numbers
(percentages) of patients unless stated otherwise
Characteristic Men (n=529 813) Women (n=542 987)
Median (interquartile range) age (years) 48 (40-57) 49 (41-59)
Mean (SD) systolic blood pressure (mm Hg) 135.6 (19.4) 132.1 (21.0)
Mean (SD) total serum cholesterol (mmol/l) 5.7 (1.1) 5.8 (1.2)
Mean (SD) high density lipoprotein cholesterol
(mmol/l)
1.3 (0.4) 1.6 (0.4)
Mean (SD) total serum cholesterol: high density
lipoprotein ratio
4.5 (1.3) 3.9 (1.2)
Mean (SD) body mass index (kg/m
2) 26.6 (4.0) 26.1 (4.9)
Current smoker 141 113 (26.6) 124 094 (22.9)
History of coronary heart disease in first degree
relative <60 years old
18 638 (3.5) 22 922 (4.2)
Receiving antihypertensive treatment 35 066 (6.6) 56 886 (10.5)
Deprivation index (Townsend score fifths):
1 (most affluent) 145 577 (27.5) 151 352 (27.9)
2 119 132 (22.5) 125 689 (23.1)
3 108 212 (20.4) 112 150 (20.7)
4 89 290 (16.9) 90 521 (16.7)
5 (most deprived) 67 602 (12.8) 63 275 (11.7)
No (%) of incident 10 year cardiovascular
disease events
25 963 (4.9) 18 027 (3.3)
10 year risk (95% CI) of cardiovascular disease
events
9.87 (9.71 to 10.03) 6.55 (6.43 to 6.68)
Total person years of observation (years) 2 603 294 2 753 924
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UsingQRISK,wecalculatedthe10yearestimatedrisk
ofcardiovasculardiseaseforeverypatientintheTHIN
cohort. We obtained observed 10 year cardiovascular
disease risks using the method of Kaplan-Meier. Miss-
ing data on three risk factors (total serum cholesterol:
high density lipoprotein ratio, systolic blood pressure,
andbodymassindex)werereplacedwithunpublished
age-sex reference values from the QRESEARCH
cohort used in the development of the QRISK risk
algorithm for all risk prediction equations. The total
serum cholesterol: high density lipoprotein ratios
were replaced by reference values matched for age
and sex, not the two individual components of this
ratio.Wheresmokingstatuswasnotindicated,patients
were assumed to be non-smokers.
Predictive performance of QRISK for the THIN
cohortwasassessedbyexaminingmeasuresofcalibra-
tion and discrimination. Calibration measures how
closely predicted 10 year cardiovascular disease risk
agrees with observed 10 year cardiovascular disease
risk. This was assessed for each tenth of predicted
risk, ensuring 10 equally sized groups, and for each
5 year age band by calculating the ratio of predicted
to observed cardiovascular disease risk, separately for
men and for women. Calibration of the model predic-
tions was assessed by plotting observed proportions
versus predicted probabilities; where a 45° line
denotes perfect calibration. The ratio of predicted to
observed 10 year cardiovascular disease risk was cal-
culated for each sex and overall, where a value of 1 is
indicativeofgoodagreement.TheBrierscorewasalso
calculated, which is a measure of accuracy and is the
average squared deviation between predicted and
observed risk; a lower score represents higher accu-
racy.
Discrimination is the ability of the risk prediction
model to differentiate between patients who experi-
ence a cardiovascular disease event during the study
and those who do not. This measure is quantified by
calculating the area under the receiver operating char-
acteristic curve (AUROC) statistic; where a value of 1
represents perfect discrimination. The cross classifica-
tionofpatientswastabulatedforthreeriskgroups(low
<10%, intermediate 10% to <20%, and high ≥20%).
We calculated the D statistic
25 and R
2 statistic
26
(derived from the D statistic), which are measures of
discrimination and explained variation respectively
and are specific to censored survival data. Higher
values of D indicate greater discrimination, and an
increase of 0.1 over other risk prediction models is a
good marker of improved prognostic separation.
25
An important aspect when introducing a new risk
prediction rule is the classification of patients into
high and low risk and the number of patients that
would be reclassified to a different risk category when
compared to the standard risk prediction approach
(here the Anderson Framingham equation). Patients
are classified as being at high risk if their predicted
risk is 20% or more.
27
We compared the performance of QRISK with esti-
mates of risk derived using the 1991 Framingham
equation
8 (termed Anderson Framingham in this
paper) and a recently developed sex-specific Framing-
ham equation (termed Cox Framingham in this
paper).
24 The Anderson Framingham equation
8 is
based on a Weibull accelerated failure time model
and is the current approach recommended in the UK
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Fig 1 | Predicted versus observed 10 year risk of cardiovascular disease for QRISK and Framingham risk equations by tenth of risk
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28
The Anderson Framingham equation recommended
by NICE was calculated by summing the risk from
two individual equations for coronary heart disease
and stroke (scores exceeding 100 are capped). The
2008 sex-specific version of Framingham is based on
the Cox proportional hazards model and is a general
cardiovascular risk score (coronary heart disease,
stroke, peripheral artery disease, or heart failure).
824
Individual cardiovascular components (for coronary
heart disease, which includes myocardial infarction
and stroke including transient ischaemic stroke) were
extracted by multiplying the general cardiovascular
score by a calibration factor
24 and were summed to
obtain a cardiovascular score (for myocardial infarc-
tion, coronary heart disease, stroke, and transient
ischaemic attack endpoints).
All statistical analyses were carried out in R (version
2.8.0).
29
RESULTS
Between 1 January 1995 and 31 March 2006, there
were 1787169 patients from 288 practices registered
intheTHINdatabase.Aftersequentiallyexcluding,as
per the exclusion criteria, 120281 patients with prior
diagnosis of cardiovascular disease, 2253 with invalid
dates, 439740 aged <35 years or ≥75 years, 114123
with missing Townsend scores, 28148 patients with a
pre-existingdiabetesdiagnosis,and9824patientswith
prior statin use, the analysed cohort consisted of
1072800 patients (see table 1). The median follow-
up was 4.9 years (range 0 to 12 years), and 36483
patients were followed for at least 10 years. The
10 year observed risk of a cardiovascular event in
men aged 35-74 years was 9.87% (95% confidence
interval 9.71% to 10.03%) and in women was 6.55%
(6.43% to 6.68%).
Complete data for all risk factors considered were
available for 26.9% of women and 25.5% of men.
There were markedly high levels of missing data for
total serum cholesterol (59.1% of women, 59.6% of
men) and high density lipoprotein (70.6% of women,
71.4%ofmen).Formostpatients(63%),oneormoreof
the three risk factors was missing (total serum choles-
terol: high density lipoprotein ratio, systolic blood
pressure, and body mass index); these had to be
replaced with the QRESEARCH age-sex reference
values. For 9% of the THIN cohort all three were not
recorded.Theobserved10yearcardiovasculardisease
risk was noticeably higher in those with complete data
recorded on risk factors (19.9% (19.5% to 20.2%) for
men, 12.8% (12.6% to 13.1%) for women) compared
with those who had at least one missing risk factor
(5.0% (4.9% to 5.2%) for men, 3.4% (3.2% to 3.5%) for
women).
Discrimination and calibration
Fig 1 visually shows the agreement between mean
observed risk and mean predicted risk grouped by
tenths of predicted risk for all three models. For both
menandwomen,theQRISKmodelgivesamoreaccu-
rate estimate of predicted risk compared with either
Framingham equation. The accuracy of the Framing-
ham equations deteriorates for those patients with
higher risk for both men and women. Both Framing-
ham equations consistently overestimate the risk for
nearly all tenths of risk for men and women. In con-
trast, QRISK underestimates risk for both men and
women.
Fig 2 shows the agreement between mean observed
risk and mean predicted risk by 5 year age bands for
both men and women. Both Framingham equations
overestimate mean risk for all age groups for men
and overestimate mean risk for women in all except
the65-69and70-74yearagegroups,inwhichitunder-
estimates risk, most notably in patients aged
70-74 years. QRISK underestimates cardiovascular
disease risk in all age groups for men and to a lesser
degree for women. QRISK provides more accurate
cardiovascular disease risk estimates in all age groups
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RESEARCH
page 4 of 10 BMJ | ONLINE FIRST | bmj.comcompared with either Framingham model except for
women aged 60-64 and 65-69 years.
Fig 3 shows the relationshipbetween cardiovascular
disease in relation to increasing age and predicted risk
fromQRISKandFraminghamequations.TheQRISK
risk algorithm approximates well to the observed
Kaplan-Meier cardiovascular disease estimates for
both men and women across all age groups. The
Anderson Framingham equation performs less well
for men and women. Also, Anderson Framingham
overestimates risk for women aged 40-64 then under-
estimates risk in women in the higher age groups, sug-
gesting that it is not fully capturing the age-female
component appropriately. Note that the Anderson
Framingham equation is a single equation with a sex
coefficient in the model, whereas QRISK comprises
two sex-specific equations.
Table 2 shows the comparisonof observed and pre-
dicted risk of cardiovascular disease at 10 years across
each tenth of risk (the first tenth represents the lowest
risk)forbothFraminghamequationsandQRISKalgo-
rithm. Overall, the Framingham equations overpre-
dicted risk at 10 years by 23% for the Anderson
Framingham model and by 18% for the Cox Framing-
ham model, whereas QRISK underpredicted risk by
12%.TheAndersonFramingham equationperformed
similarlyinwomenwhencomparedwithQRISK,with
Anderson Framingham overpredicting risk by 10%
across the tenths of risk compared with an underpre-
dictionof10%byQRISK.TheCoxFraminghamover-
predicted the risk in women overall by only 4%, but
this impressive performance is likely to be because
the Cox Framingham overpredicts risk for women
aged 35-64 years yet underpredicts risk for women
aged≥65,thusaveragingouttoanartificiallygoodper-
formance (fig 2). In men, both Framingham equations
consistently overpredict risk in each tenth and overall
by 32% and 25% for the Anderson Framingham and
Cox Framingham model respectively. This compares
with an overall underprediction of 13% by QRISK.
Table 3 shows discrimination and calibration per-
formance data for QRISK and both Framingham
equations. The R
2 statistic (percentage of explained
variation) is higher for QRISK in both men and
women (31.7% and 36.6% respectively) compared
with the next best model, the Cox Framingham equa-
tion (29.5% and 32.3% respectively). The D discrimi-
nation statistic, where a higher value represents better
discrimination, is higher in both men and women for
QRISK(1.39and1.56respectively).FortheAnderson
Framingham equation, the corresponding D statistic
values for men and women were 1.26 and 1.38 respec-
tively; values lower than the corresponding QRISK
valuesby more than 0.1,indicatingpoorer discrimina-
tion of the Anderson Framingham. The Brier score,
which is a measure of accuracy, was lower (that is,
Table 2 |Ratio of predicted to observed risks of 10 year cardiovascular disease event for QRISK and Framingham risk
equations across tenths of predicted risk and overall
Tenth of risk
QRISK Anderson Framingham Cox Framingham
Predicted
risk (%)
Observed
risk (%) Ratio
Predicted
risk (%)
Observed
risk (%) Ratio
Predicted
risk (%)
Observed
risk (%) Ratio
Women:
First 0.67 0.49 1.36 0.62 0.67 0.92 1.18 0.81 1.46
Second 1.00 1.02 0.98 1.23 1.08 1.14 1.76 1.06 1.66
Third 1.42 1.32 1.07 2.03 1.58 1.28 2.35 1.57 1.50
Fourth 2.03 2.00 1.01 3.15 2.65 1.19 3.08 2.31 1.33
Fifth 2.90 3.04 0.95 4.56 3.78 1.21 4.02 3.30 1.22
Sixth 4.09 4.30 0.95 6.25 5.32 1.18 5.28 4.78 1.10
Seventh 5.79 6.36 0.91 8.21 7.73 1.06 6.96 7.31 0.95
Eighth 8.32 9.44 0.88 10.55 9.06 1.16 9.29 9.28 1.00
Ninth 12.27 13.73 0.89 13.71 12.77 1.07 12.83 12.50 1.03
Tenth 20.46 20.19 1.01 21.55 17.49 1.23 21.96 18.42 1.19
Overall 5.89 6.55 0.90 7.19 6.55 1.10 6.87 6.55 1.04
Men:
First 1.52 1.26 1.21 2.93 2.11 1.39 2.73 1.58 1.73
Second 2.12 2.17 0.97 4.34 2.59 1.67 3.87 2.26 1.71
Third 2.80 2.86 0.98 5.74 3.61 1.59 5.11 3.04 1.68
Fourth 3.72 3.93 0.95 7.31 4.61 1.59 6.50 4.44 1.46
Fifth 4.96 5.59 0.89 9.18 6.33 1.45 8.18 5.87 1.39
Sixth 6.59 8.08 0.82 11.43 8.24 1.39 10.29 7.71 1.33
Seventh 8.75 10.42 0.84 14.19 10.44 1.36 13.06 10.83 1.21
Eighth 11.87 14.56 0.82 17.82 14.36 1.24 16.83 13.91 1.21
Ninth 16.66 19.89 0.84 22.87 18.10 1.26 22.29 18.77 1.19
Tenth 26.62 26.26 1.01 34.27 24.83 1.38 35.18 26.17 1.34
Overall 8.56 9.87 0.87 13.01 9.87 1.32 12.39 9.87 1.25
All patients 7.21 8.16 0.88 10.10 8.16 1.23 9.60 8.16 1.18
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witheithertheAndersonFramingham(0.0545)orCox
Framingham equation (0.0530). Similarly, for women,
the Brier score was lower for QRISK (0.0321) com-
pared with the Anderson Framingham (0.0334) and
Cox Framingham equations (0.0330).
Risk classification
With a threshold of 20% to identify high risk patients,
Anderson Framingham would identify 20% of the
male cohort and 5% of the female cohort as being at
high risk, compared with 10% and 4% respectively
with QRISK. Table 4 shows the number of patients
who would be reclassified from high risk (≥20%) with
the Anderson Framingham equation to low risk
(<20%) with QRISK and vice versa, and the average
predicted and observed risks. In total, 85010 patients
(71% men, 29% women) would be reclassified (8%), of
whom 57199 men (67%) and 13566 women (16%)
would be downgraded from high risk with the Ander-
son Framingham to low risk with QRISK. In these
patients, the observed 10 year cardiovascular disease
risk was 17.5% (95% confidence interval 16.9% to
18.1%) for men and 16.8% (15.7% to 18.0%) for
women. Conversely, 3548 men (4%) and 10697
women (13%) would be reclassified from low risk
with Anderson Framingham to high risk with
QRISK, with observed 10 year cardiovascular disease
risks of 25.5% (23.1% to 28.1%) and 23.1% (21.6% to
24.7%) respectively.
The incidence rate of cardiovascular events among
men designated high risk with QRISK was 30.5 per
1000 person years (95% confidence interval 29.9 to
31.2), whereas it was 23.7 per 1000 person years (23.2
to 24.1) with the Anderson Framingham equation.
Similarly, for women identified as high risk with
QRISK, the incidence rate of cardiovascular events
was 26.7 per 1000 person years (25.8 to 27.7) and was
22.2 per 1000 person years (21.4 to 23.0) with Ander-
son Framingham. Thus, using the 20% threshold to
identify high risk patients, QRISK identified a group
of patients at a higher risk of a cardiovascular event
than those identified with Anderson Framingham.
Conversely, the incidence rates among those not
identified as being at high risk (<20%) was 7.8 per
1000 person years (7.6 to 7.8) for men and 6.5 per
1000 person years (6.4 to 6.6) for women with
QRISK and 5.6 per 1000 person years (5.5 to 5.6) for
men and 5.7 per 1000 person years (5.6 to 5.8) for
women with Anderson Framingham.
In a similar manner to table 4, tables 5 and 6 show
thecrossclassificationofpatientsintothreeriskgroups
—<10% (low), 10 to <20% (intermediate), and ≥20%
(high)—by QRISK and the Anderson Framingham
equation, along with predicted and observed cardio-
vascular disease risk. Of the 106265 men identified at
being at high risk with Anderson Framingham, 57199
(53.8%) would be reclassified as being at low risk (3%)
or intermediate risk (50.9%). The observed risk of the
Table 3 |Discrimination and calibration statistics for predicted 10 year risk of cardiovascular disease by QRISK and
Framingham risk equations
Statistic
QRISK Anderson Framingham Cox Framingham
Men Women Men Women Men Women
AUROC 0.762 0.789 0.737 0.761 0.752 0.770
D statistic (95% CI) 1.39 (1.38 to
1.41)
1.56 (1.53 to
1.58)
1.26 (1.24 to
1.28)
1.38 (1.35 to
1.40)
1.33 (1.31 to
1.34)
1.41(1.39to1.44)
R
2 statistic (95% CI) 31.71 (31.09 to
32.31)
36.64 (35.94 to
37.34)
27.31 (26.69 to
27.93)
31.18 (30.45 to
31.91)
29.52 (28.91 to
30.14)
32.32 (31.59 to
33.04
Brier score* 0.0470 0.0321 0.0545 0.0334 0.0530 0.0330
Predicted/observed 0.87 0.90 1.32 1.10 1.25 1.04
Predicted/observed
(overall)
0.88 1.23 1.18
*A lower score indicates better accuracy of risk estimates
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Fig 3 | Predicted versus observed (Kaplan-Meier) 10 year risk
of cardiovascular disease for QRISK and Framingham risk
equations by 5 year age bands
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(17.1% to 18.3%). Similarly, for women, of the 25812
patientsidentified at being at highrisk withthe Ander-
son Framingham equation, 13566 patients (52.6%)
would be downgraded into low (3.6%) and inter-
mediate risk (48.9%). The observed risk of the patients
downgraded to intermediate risk was 16.9% (15.8% to
18.1%). In contrast, 10010 women identified as being
at intermediate risk with Anderson Framingham were
identified by QRISK as being at high risk, with an
observed risk of 22.7% (95 21.2% to 24.3%).
Finally,theFraminghamequationspredictedthat,of
one million men identified at being at high risk, the
number who would have a cardiovascular event over
the next 10 years is 141111 (Cox Framingham) and
116896 (Anderson Framingham). Similarly, the num-
ber of high risk women expected to have a cardio-
vascular event over the next 10 years is 126143 (Cox
Framingham) and 119905 (Anderson Framingham).
However, in one million men and one million
women identified as being at high risk with QRISK,
the expected number that will go on to have a cardio-
vascular event in the next 10 years is higher at 147204
and 140217 respectively.
DISCUSSION
Principle findings
Inthislargecohortofpatients,theAndersonFraming-
ham equation
8 overestimated the 10 year risk of
cardiovascular disease by 32% in men, by 10% in
women,andby23%overall.ThenewerCoxFraming-
ham equation showed an improvement over the
Anderson Framingham equation by overpredicting
cardiovascular disease risk by 25% in men and by
18% overall, and it compared favourably with both
Anderson Framingham and QRISK in women by
overpredicting risk for the entire female cohort by
only 4%. However, this value gives a false impression
by averaging out overprediction in younger women
and underprediction in older women to an artificially
good performance. With QRISK, 10 year cardio-
vascular disease risk was underpredicted by 13% for
men, by 10% for women, and by 12% overall, but this
model provides the most accurate predictions of
10 year cardiovascular disease risk in this large UK
cohort. This finding is probably not surprising, as
QRISK was developed on a separate but equally
large cohort of patients in the UK and is thus more
tailored to the UK population. In addition, QRISK
contains additional risk factors—social deprivation,
bodymassindex,familyhistory,andcurrenttreatment
with antihypertensives—which are known to affect
cardiovascular disease risk
30 and that are not included
in either of the Framingham equations.
On the evidence presented in this paper, the Fra-
mingham equations in their present form clearly over-
predict 10 year cardiovascular disease risk in the
United Kingdom, and this is more noticeable for
men. In the THIN cohort, 20% of the male population
would be identified at being at high risk of a cardio-
vascular disease event over the next 10 years, com-
pared with just 10% if the QRISK algorithm had been
used. Yet, if one million male patients and one million
female patients identified as being at high risk were
followed, then the number of cardiovascular disease
events over the next 10 years will be 25% and 17%
higher in men and women respectively with QRISK
compared with Anderson Framingham, indicating
that QRISK will target more high risk patients that
would benefit from treatment.
Table 4 |Comparison of QRISK and Anderson Framingham risk equation in classification of patients’ 10 year risk of
cardiovascular disease (low (<20%) or high (≥20%)) and observed and predicted risk
Anderson Framingham
QRISK
Men Women
Low risk High risk Low risk High risk
Low risk
No of patients 420 000 3 548 506 478 10 697
No of cardiovascular events 12 975 566 13 486 1 446
% of patients classified 79.3 0.7 93.3 2.0
Average predicted risk of
cardiovascular event (%):
QRISK 5.4 24.7 4.8 23.8
Anderson Framingham 9.0 17.00 6.1 15.2
Observed risk % (95% CI) 6.5 (6.4 to 6.7) 25.5 (23.1 to 28.1) 5.3 (5.2 to 5.5) 23.1 (21.6 to 24.7)
High risk
No of patients 57 199 49 066 13 566 12 246
No of cardiovascular events 5 243 7 179 1 324 1 771
% of patients classified 10.8 9.3 2.50 2.3
Average predicted risk of
cardiovascular event (%):
QRISK 15.2 26.8 15.3 25.9
Anderson Framingham 24.6 33.1 23.9 28.0
Observed risk % (95% CI) 17.5 (16.9 to 18.1) 26.3 (25.6 to 27.1) 16.8 (15.7 to 18) 24.2 (22.9 to 25.6)
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There were high levels of missing data in this THIN
cohort,especiallyfortheriskfactortotalserumcholes-
terol: high density lipoprotein ratio. Most patients
(79%) had at least one missing risk factor (from total
serum cholesterol: high density lipoprotein ratio, sys-
tolic blood pressure, or body mass index) which
required reference values (matched for age and sex)
to be used. As one would expect, the observed
10 year cardiovascular disease risk was higher among
patients with complete data on risk factors compared
with those with at least one missing risk factor, as a
consequence of those patients who visit their general
practitioner for health-related problems being more
likely to have these risk factors measured. The high
amounts of missing data for total serum cholesterol
and high density lipoprotein cholesterol were also
observed in the development of QRISK from the
QRESEARCH dataset, which uses the EMIS compu-
ter system.
Recent criticisms regarding missing data and ques-
tions about uncertainty on the accuracy of QRISK are
misinformed and unfounded.
21 The original
development and validation,
7 the subsequent external
validation,
13andthiscommissionedexternalandinde-
pendent validation and evaluation of QRISK have
shown, on extremely large cohorts, that QRISK pro-
vides the scientific community with a risk prediction
algorithm that performs better than the currently
recommended Anderson Framingham risk score.
Our independent evaluation was carried out using a
different statistical software package (R version 2.8.0)
from that used by the QRISK authors (Stata version
9.2), further supporting material presented in this arti-
cle.
Readers may query whether the Framingham equa-
tions should be recalibrated to the UK population, so
that the performance of the recalibrated model could
then compare more favourably with QRISK.
21 Our
brief was to independently compare QRISK with the
current model recommended in the Joint British
Society Guidelines,
28 which is the standard Anderson
Framingham equation, a model developed on a com-
paratively small (n=5573), homogenous white sample
from a single town in the US between 1968 and 1975.
Undoubtedly, a recalibrated model could be expected
to be more competitive, but at present no such recali-
brated model exists in the public domain.
Another cardiovascular risk score, ASSIGN, has
relatively recently been published, which in common
with QRISK includes family history and social depri-
vationriskfactors.
31ASSIGNisarisk scoredeveloped
using cohorts of Scottish men (n=6540) and women
(n=6757) recruited in the 1980s and 1990s from the
Scottish Heart Health Study,
32 when the incidence of
cardiovascular disease was higher than in England.
33
However, comparison against ASSIGN was not possi-
ble in this validation study, as the social deprivation
index used in ASSIGN (Scottish Index of Multiple
Deprivation) is not recorded in the THIN database
and there is no direct conversion to the Townsend
index. Similarly, the number of cigarettes smoked
(required to calculate the ASSIGN score) is not col-
lected within the THIN database, only whether a
patient smokes.
Future research
A modified version of QRISK (QRISK2) has recently
beendevelopedwhichincludesethnicitytoaccountfor
the increased risk in south Asian men and women in
the United Kingdom.
34 Initial results comparing this
new model to the original QRISK and the Anderson
Framingham equation recommended by NICE show
an improvement in performance, but further indepen-
dentvalidationonanexternalcohortofpatientswould
be required.
Conclusions
In this study, we have provided an independent and
external validation of the QRISK risk score on a
large cohort of patients. We have assessed the perfor-
mance of QRISK against the current NICE recom-
mended model and have provided evidence to
Table 5 |Comparison of QRISK and Anderson Framingham risk equation in classification of
male patients’ 10 year risk of cardiovascular disease (low (<10%), intermediate (10% to
<20%), high (≥20%)) and observed and predicted risk
Anderson Framingham
QRISK
Total No (%) of
patients reclassified
Low
risk
Intermediate
risk
High
risk
Low risk
No of patients 257 315 1 213 46
1 259 (0.2)
No of cardiovascular events 4 130 197 21
% of patients classified 48.6 0.2 <0.1
Average predicted risk of
cardiovascular event (%):
QRISK 3.1 12.3 23.4
Anderson Framingham 5.8 8.5 8.6
Observed risk % (95% CI) 3.7(3.5to3.85) 28.3 (23.3 to
33.1)
—
Intermediate risk
No of patients 108 539 52 933 3 502
112 041 (21.1)
No of cardiovascular events 4 113 4 535 545
% of patients classified 20.5 10.0 0.7
Average predicted risk of
cardiovascular event (%):
QRISK 7.1 12.9 24.8
Anderson Framingham 13.1 16.6 17.1
Observed risk % (95% CI) 7.7 (7.4 to 8.0) 16.3 (15.7 to
17.0)
25.0 (22.4 to
27.4)
High risk
No of patients 3 162 54 037 49 066
57 199 (9.8)
No of cardiovascular events 235 5 008 7 179
% of patients classified 0.6 10.2 9.3
Average predicted risk of
cardiovascular event (%):
QRISK 8.7 15.6 26.8
Anderson Framingham 22.8 24.7 33.1
Observed risk % (95% CI) 14.3 (12.0 to
16.5)
17.7 (17.1 to
18.3)
26.3 (25.6 to
27.1)
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Framingham equation.
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